How urinary function is acquired and why it deteriorates in aging men to cause lower urinary tract symptoms (LUTS) is not known. Our compelling new preliminary results conclusively demonstrate that from gestation through adulthood, DNA methylation shapes urinary function. We provide evidence that DNA methylation establishes adult voiding behavior by controlling prostate glandular development in the fetus. We show that it maintains adult voiding behavior through a parallel mechanism. Most importantly, we reveal that it can be targeted to prevent urinary dysfunction. A pharmacological DNA methylation enhancer, when given to mice prone to urinary obstruction, restores DNA methylation, prevents inappropriate gland growth, and improves urinary output, a therapeutic goal in men with obstructive voiding symptoms. The central hypothesis is that from gestation to adulthood, DNA methylation controls androgen receptor expression to restrict prostate androgen responsiveness, control glandular growth and influence urinary outflow. We term this hypothesis Epigenetic Enhancement of Androgen Action (EEAA).
Specific aims will determine whether: (1) Fetal prostate DNA methylation establishes adult urinary function, (2) Adult prostate DNA methylation maintains appropriate gland density by restricting growth, (3) Adult prostate DNA methylation prevents urinary dysfunction. The overarching goal is to establish a new mechanistic connection between prostate DNA methylation and urinary physiology that identifies an underlying basis of urinary function and a new therapeutic target for treating LUTS.
Most aging men will develop LUTS with advanced age and many will require treatment. Factors that impact androgen action have a clear role in prostate gland growth and obstructive LUTS. Our preliminary results represent the discovery of an entirely new link between prostate DNA methylation and androgen responsiveness, glandular growth, and urinary dysfunction. Not only does the proposed research have a high likelihood of providing new knowledge of how urinary dysfunction arises, it also has a very high probability of discovering new therapies for preventing or treating an underlying cause of LUTS.
|Hill, Warren G; Zeidel, Mark L; Bjorling, Dale E et al. (2018) The void spot assay: Recommendations on the use of a simple micturition assay for mice. Am J Physiol Renal Physiol :|
|Wegner, Kyle A; Abler, Lisa L; Oakes, Steven R et al. (2018) Void spot assay procedural optimization and software for rapid and objective quantification of rodent voiding function, including overlapping urine spots. Am J Physiol Renal Physiol 315:F1067-F1080|
|Ruetten, Hannah; Wegner, Kyle A; Romero, Michael F et al. (2018) Prostatic collagen architecture in neutered and intact canines. Prostate 78:839-848|
|Joseph, Diya B; Chandrashekar, Anoop S; Abler, Lisa L et al. (2018) In vivo replacement of damaged bladder urothelium by Wolffian duct epithelial cells. Proc Natl Acad Sci U S A 115:8394-8399|
|Wegner, Kyle A; Cadena, Mark T; Trevena, Ryan et al. (2017) An immunohistochemical identification key for cell types in adult mouse prostatic and urethral tissue sections. PLoS One 12:e0188413|
|Wegner, Kyle A; Keikhosravi, Adib; Eliceiri, Kevin W et al. (2017) Fluorescence of Picrosirius Red Multiplexed With Immunohistochemistry for the Quantitative Assessment of Collagen in Tissue Sections. J Histochem Cytochem 65:479-490|
|Mulligan, William A; Wegner, Kyle A; Keil, Kimberly P et al. (2017) Beta-catenin and estrogen signaling collaborate to drive cyclin D1 expression in developing mouse prostate. Differentiation 93:66-71|
|Keil, Kimberly P; Abler, Lisa L; Altmann, Helene M et al. (2016) Influence of animal husbandry practices on void spot assay outcomes in C57BL/6J male mice. Neurourol Urodyn 35:192-8|
|Ricke, William A; Lee, Calvin W; Clapper, Tyler R et al. (2016) In Utero and Lactational TCDD Exposure Increases Susceptibility to Lower Urinary Tract Dysfunction in Adulthood. Toxicol Sci 150:429-40|
|Bauman, Tyler M; Vezina, Chad M; Ricke, Emily A et al. (2016) Expression and colocalization of ?-catenin and lymphoid enhancing factor-1 in prostate cancer progression. Hum Pathol 51:124-33|
Showing the most recent 10 out of 17 publications